GRAIL, Inc. (NASDAQ:GRAL) Receives Average Rating of “Hold” from Analysts

GRAIL, Inc. (NASDAQ:GRAL) has received an average rating of “Hold” from the ten ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $67.7778.

Several brokerages recently weighed in on GRAL. TD Cowen reissued a “buy” rating on shares of GRAIL in a research note on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research report on Friday, July 17th. Piper Sandler lifted their target price on GRAIL from $54.00 to $56.00 and gave the stock a “neutral” rating in a report on Wednesday, May 6th. Wall Street Zen upgraded GRAIL from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Robert W. Baird set a $70.00 price target on GRAIL in a research note on Wednesday, May 6th.

Insider Activity at GRAIL

In related news, insider Andrew John Partridge sold 1,491 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $61.08, for a total value of $91,070.28. Following the sale, the insider directly owned 163,738 shares in the company, valued at $10,001,117.04. This represents a 0.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.83% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in shares of GRAIL by 20.5% in the 2nd quarter. BlackRock Inc. now owns 3,577,075 shares of the company’s stock valued at $244,207,000 after purchasing an additional 608,539 shares during the last quarter. Farallon Capital Management LLC raised its stake in GRAIL by 73.7% during the fourth quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company’s stock worth $200,510,000 after buying an additional 993,684 shares during the last quarter. Baker BROS. Advisors LP raised its stake in GRAIL by 27.9% during the fourth quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock worth $178,484,000 after buying an additional 455,208 shares during the last quarter. Vanguard Group Inc. lifted its holdings in GRAIL by 9.0% in the fourth quarter. Vanguard Group Inc. now owns 1,980,783 shares of the company’s stock valued at $169,535,000 after buying an additional 163,790 shares during the period. Finally, State Street Corp lifted its holdings in GRAIL by 38.8% in the fourth quarter. State Street Corp now owns 1,827,523 shares of the company’s stock valued at $156,418,000 after buying an additional 510,546 shares during the period.

GRAIL Price Performance

GRAL opened at $68.94 on Thursday. GRAIL has a fifty-two week low of $29.95 and a fifty-two week high of $118.84. The company’s 50 day moving average price is $67.39 and its two-hundred day moving average price is $65.59. The firm has a market capitalization of $3.08 billion, a price-to-earnings ratio of -7.07 and a beta of 3.24.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.66) by $0.10. The firm had revenue of $44.69 million during the quarter, compared to the consensus estimate of $42.39 million. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. As a group, equities research analysts predict that GRAIL will post -10.41 EPS for the current year.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.